Opposing adrenergic actions of intravenous metformin on arterial pressure in female spontaneously hypertensive rats

被引:16
作者
Peuler, JD [1 ]
机构
[1] Midwestern Univ, Dept Pharmacol, Downers Grove, IL 60515 USA
关键词
experimental; regulatory systems; pharmacology; autonomic nervous system; blood pressure; diabetes; hypertension; vasoconstriction dilation;
D O I
10.1016/S0008-6363(99)00051-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Intravenous (iv) injection of the antidiabetic drug metformin rapidly lowers mean arterial pressure (MAP) in spontaneously hypertensive rats (SHR). However, if autonomic ganglia or alpha-adrenoceptors are first blocked then metformin rapidly raises MAP in SHR. This study was conducted to further characterize the adrenergic mechanisms of these opposing iv actions of the drug, Methods: Conscious, undisturbed female SHR with indwelling vascular catheters were used to measure acute effects of iv metformin (100 mg/kg; before and after sustained ganglionic blockade, GB, with chlorisondamine, 5 mg/kg) on: (1) circulating levels of catecholamines, (2) MAP after pharmacologic modulation of beta- as well as alpha-adrenoceptors and (3) all the above in the absence as well as presence of the adrenal medulla. Results: Plasma norepinephrine (NE) and epinephrine (E) levels (pg/ml) were rapidly increased by iv metformin (8 SHR, p<0.05) both before GB (Delta NE = +146 +/- 41; Delta E = +119 +/- 31) and after GB (Delta NE = +79 +/- 24; Delta E = +120 +/- 32). Similar increases in plasma NE (though not E) were seen in SHR without adrenal medullae. Blockade of beta-adrenoceptors with propranolol (pro; 3 mg/kg, 8 SHR) enhanced the rapid depressor response to iv metformin before GB (Delta MAP, mmHg: -38 +/- 4 with pro vs -17 +/- 3 without pro; p<0.05) and attenuated the rapid presser response to iv metformin after GB (Delta MPAP, mmHg: +8 +/- 3 with pro vs +30 +/- 4 without pro; p<0.05). Results were similar in SHR without adrenal medullae. Finally, if baseline MAP under GB was raised back to hypertensive levels with iv infusion of either NE or phenylephrine then iv metformin did not raise but rather reduced MAP in SHR. Conclusion(s): The acute depressor action of iv metformin in female SHR (1) is most likely due to a direct vasodilator action which includes inhibition of alpha-receptor-mediated vasoconstriction and (2) is buffered by an acute beta-receptor-mediated presser action likely due to a direct metformin-induced release of NE from postganglionic sympathetic nerve endings. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:237 / 247
页数:11
相关论文
共 37 条
[1]  
ABDELRAHMAN ARA, 1989, ARCH INT PHARMACOD T, V297, P68
[2]  
CALLEPASCUAL AL, 1995, DIABETES METAB, V21, P256
[3]   THE EFFECT OF METFORMIN ON GLYCEMIC CONTROL, INTERMEDIARY METABOLISM AND BLOOD-PRESSURE IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS [J].
CAMPBELL, IW ;
DUNCAN, C ;
PATTON, NW ;
BROADHEAD, T ;
TUCKER, GT ;
WOODS, HF .
DIABETIC MEDICINE, 1987, 4 (04) :337-341
[4]   METABOLIC AND HEMODYNAMIC-EFFECTS OF METFORMIN AND GLIBENCLAMIDE IN NORMOTENSIVE NIDDM PATIENTS [J].
CHAN, JCN ;
TOMLINSON, B ;
CRITCHLEY, JAJH ;
COCKRAM, CS ;
WALDEN, RJ .
DIABETES CARE, 1993, 16 (07) :1035-1038
[5]   Metformin relaxes rat tail artery by repolarization and resultant decreases in Ca2+ influx and intracellular [Ca2+] [J].
Chen, XL ;
Panek, K ;
Rembold, CM .
JOURNAL OF HYPERTENSION, 1997, 15 (03) :269-274
[6]   Improvement of insulin sensitivity by metformin treatment does not lower blood pressure of nonobese insulin-resistant hypertensive patients with normal glucose tolerance [J].
Dorella, M ;
Giusto, M ;
DaTos, V ;
Campagnolo, M ;
Palatini, P ;
Rossi, G ;
Ceolotto, G ;
Felice, M ;
Semplicini, A ;
DelPrato, S .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (04) :1568-1574
[7]   Metformin's effects on glucose and lipid metabolism in patients with secondary failure to sulfonylureas [J].
Fanghanel, G ;
SanchezReyes, L ;
Trujillo, C ;
Sotres, D ;
EspinosaCampos, J .
DIABETES CARE, 1996, 19 (11) :1185-1189
[8]   The effect of metformin on the metabolic abnormalities associated with upper-body rat distribution [J].
Fontbonne, A ;
Charles, MA ;
JuhanVague, I ;
Bard, JM ;
Andre, P ;
Isnard, F ;
Cohen, JM ;
Grandmottet, P ;
Vague, P ;
Safar, ME ;
Eschwege, E .
DIABETES CARE, 1996, 19 (09) :920-926
[9]   METFORMIN IMPROVES GLUCOSE, LIPID-METABOLISM, AND REDUCES BLOOD-PRESSURE IN HYPERTENSIVE, OBESE WOMEN [J].
GIUGLIANO, D ;
DEROSA, N ;
DIMARO, G ;
MARFELLA, R ;
ACAMPORA, R ;
BUONINCONTI, R ;
DONOFRIO, F .
DIABETES CARE, 1993, 16 (10) :1387-1390
[10]   METFORMIN FOR OBESE, INSULIN-TREATED DIABETIC-PATIENTS - IMPROVEMENT IN GLYCEMIC CONTROL AND REDUCTION OF METABOLIC RISK-FACTORS [J].
GIUGLIANO, D ;
QUATRARO, A ;
CONSOLI, G ;
MINEI, A ;
CERIELLO, A ;
DEROSA, N ;
DONOFRIO, F .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 44 (02) :107-112